🇪🇺 voriconazole (VFEND®) in European Union

EMA authorised voriconazole (VFEND®) on 19 March 2002

Marketing authorisation

EMA — authorised 19 March 2002

  • Application: EMEA/H/C/000387
  • Marketing authorisation holder: Pfizer Europe MA EEIG
  • Local brand name: Vfend
  • Indication: Voriconazole, is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows: treatment of invasive aspergillosis; treatment of in candidaemianon-neutropenic patients; treatment of fluconazole-resistant serious invasive Candida infections (including C. krusei); Treatment of serious fungal infections caused by Scedosporium spp. and Fusarium spp. Vfend should be administered primarily to patients with progressive, possibly life-threatening infections. Prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem c
  • Status: approved

Read official source →

Other Infectious Diseases approved in European Union

Frequently asked questions

Is voriconazole (VFEND®) approved in European Union?

Yes. EMA authorised it on 19 March 2002.

Who is the marketing authorisation holder for voriconazole (VFEND®) in European Union?

Pfizer Europe MA EEIG holds the EU marketing authorisation.